The firm is a U.S.-based venture capital platform providing smart capital to early-stage companies in medicine, biotech, and bioengineering. The firm focuses on opportunities at the intersection of biotechnology and computation or AI. The firm’s investment sweet spot is between Seed and Series A, with initial check sizes typically ranging from $250K–$300K and up to $500K, with the potential for follow-on investments. The firm is open to both leading and co-investing and does not have specific requirements regarding board or observer seats. The firm primarily focuses on companies based in the United States.
The firm invests in techbio opportunities that combine biotechnology with computational or AI-driven approaches. The firm is less interested in digital health companies that do not have a biotech or wet-lab component and prioritizes highly innovative technologies with novel mechanisms rather than incremental improvements. Modalities of interest include gene therapy, cell therapy, mRNA-based therapies, and platform technologies. The firm is indication-agnostic. From a development-stage perspective, the firm is most interested in assets at the preclinical stage or entering early clinical development, supported by in vitro and/or animal model data.
The firm does not have specific requirements regarding the composition of a company’s management team.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment